FindTrial
Sign In

Understanding the Clinical Benefits of Gliclazide in Type 2 Diabetes: An Indian KAP Study

LEveraging Insights on the Clinical Relevance of GliclAzide for GluCo-Centric & BeYond Benefits in T2DM Care Continuum: An Indian KAP Study (LEGACY-INDIA) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/107639
Enrollment
250
Registered
2026-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Dr. Reddys Laboratories Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Endocrinologists, diabetologists, consultant physicians, healthcare professionals practicing at healthcare setups ,clinics ,hospitals located across various regions of India

Exclusion criteria

Exclusion criteria: 1. Healthcare professionals unwilling to participate in the KAP study 2. Healthcare professionals not treating patients with diabetes

Design outcomes

Primary

MeasureTime frame
1. To understand the knowledge, attitude, and practice, KAP, patterns of Indian clinicians regarding the clinical importance and relevance of gliclazide (in glucose control and microvascular complications) 2. To seek practical insights regarding gliclazide application in the real-world Indian T2DM clinical care continuum.Timepoint: Day 1—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Syed Mujtaba Hussain Naqvi

Dr. Reddys Laboratories Ltd.

mujtabanaqvi@drreddys.com7032969523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026